Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma

Both sunitinib, a multi-target tyrosine kinase inhibitor (TKI) and propranolol, a non-selective β-blocker, have proven therapeutic effects on malignant melanoma (MM). This study reports a synergistic effect of propranolol and sunitinib upon A375, P8 MM cell lines and mice xenografts. Cell viability...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Xinwei, Qi, Min, Peng, Cong, Zhou, Chengfang, Su, Juan, Zeng, Weiqi, Liu, Hong, Zhang, Jianglin, Chen, Mingliang, Shen, Minxue, Xie, Xiaoyun, Li, Fangfang, Zhao, Shuang, Li, Qingling, Luo, Zhongling, Chen, Junchen, Tao, Juan, He, Yijing, Chen, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787512/
https://www.ncbi.nlm.nih.gov/pubmed/29416656
http://dx.doi.org/10.18632/oncotarget.22696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787512/
https://www.ncbi.nlm.nih.gov/pubmed/29416656
http://dx.doi.org/10.18632/oncotarget.22696

Ejemplares similares